Illumina, Inc. (ILMN): Price and Financial Metrics
Illumina, Inc. (ILMN)
Today's Latest Price: $305.50 USD
Updated Sep 29 4:00pm
Add ILMN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ILMN Stock Summary
- Illumina Inc's market capitalization of $44,597,160,000 is ahead of 95.65% of US-listed equities.
- The price/operating cash flow metric for Illumina Inc is higher than 90.12% of stocks in our set with a positive cash flow.
- ILMN's price/sales ratio is 13.31; that's higher than the P/S ratio of 89.42% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Illumina Inc are NTES, ADI, SPOT, DXCM, and BIIB.
- Visit ILMN's SEC page to see the company's official filings. To visit the company's web site, go to www.illumina.com.
ILMN Stock Price Chart Technical Analysis Charts
ILMN Price/Volume Stats
| Current price | $305.50 | 52-week high | $404.20 |
| Prev. close | $305.46 | 52-week low | $196.78 |
| Day low | $302.37 | Volume | 1,611,186 |
| Day high | $309.70 | Avg. volume | 1,284,918 |
| 50-day MA | $349.38 | Dividend yield | N/A |
| 200-day MA | $324.86 | Market Cap | 44.60B |
Illumina, Inc. (ILMN) Company Bio
Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.
ILMN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $305.50 | $153.34 | -50% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Illumina Inc. To summarize, we found that Illumina Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for ILMN, they are:
- Interest coverage, a measure of earnings relative to interest payments, is 21.05; that's higher than 86.13% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than just 12.29% of the free cash flow producing stocks we're observing.
- ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 46.05% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -51% |
| 1% | -50% |
| 2% | -50% |
| 3% | -49% |
| 4% | -49% |
| 5% | -48% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ILMN, try LMAT, GILD, HAPP, ZTS, and CPIX.
Loading social stream, please wait...